Drugs / Zavegepant
Zavegepant
also known as
BHV3500 · PF-07930207 · BHV-3500 hydrochloride · BMS-742413 · BMS-742413 hydrochloride · BMS-742413-01 · BMS-742413-03 · vazegepant · +2 more
Small molecule targets CALCRL via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ZAVZPRET | — | 2023-03-09 | fda.gov ↗ |
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07667621 | Jul 2026 → Jul 2027 expected | migraine with aura, migraine without aura | University of South Florida | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06995729 | May 2025 → Aug 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT06453356 | Jun → Sep 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05960032 | Oct → Dec 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05948085 | Jul → Sep 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06137703 | Aug → Dec 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04987944 | Oct 2021 → Mar 2023 | asthma | Pfizer | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07714369 | Oct 2026 → Apr 2028 expected | cluster headache syndrome | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04408794 | Jun 2020 → Dec 2021 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT04346615 | Apr 2020 → Apr 2022 | COVID-19 | Pfizer | Terminated | No outcome recorded |
| Phase 2/3 | NCT03872453 | Mar → Oct 2019 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06103734 | Sep 2025 → Aug 2027 | migraine disorder | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT05989048 | Nov 2023 → May 2025 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04571060 | Oct 2020 → Oct 2021 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06985342 | Jun 2025 → Jan 2026 | migraine disorder | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 4 | NCT06401642 | Mar 2024 → Mar 2027 expected | migraine disorder | Mayo Clinic | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04804033 Comparator | Mar 2021 → Mar 2024 | migraine disorder | Pfizer | Terminated | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-10 | Pfizer | Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval pfizer.com ↗ |
| 2023-02-16 | Pfizer | Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults pfizer.com ↗ |
| 2022-01-05 | Pfizer | Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States pfizer.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zavegepant | “The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number...” NCT04804033 ↗ |
| Known as | BHV-3500 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397415 ↗ |
| Known as | BHV3500 | “* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).” NCT04346615 ↗3“Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule” NCT06137703 ↗ “BHV-3500, formerly "vazegepant", is now referred to as "zavegepant"” NCT04408794 ↗ |
| Known as | BMS-742413 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397415 ↗ |
| Known as | BMS-742413 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397415 ↗ |
| Known as | BMS-742413-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397415 ↗ |
| Known as | BMS-742413-03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397415 ↗ |
| Known as | PF-07930207 | “A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine” NCT06995729 ↗1“Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule” NCT06137703 ↗ |
| Known as | vazegepant | “* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).” NCT04346615 ↗ |
| Known as | ZAVEGEPANT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397415 ↗ |
| Known as | Zavzpret | “Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US.” NCT06401642 ↗ |
| Action | Inhibit | “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL2397415 ↗1“CGRP receptor antagonist” NCT04346615 ↗ |
| Modality | Small molecule | “ZAV 10-mg nasal spray is the first intranasal, small-molecule CGRP receptor antagonist approved for the acute treatment of migraine with or without aura in adults.” PMID 40391567 ↗ May 2025 |
| Route | Intranasal | “single intranasal dose of zavegepant 5 mg” NCT03872453 ↗ |
| Target | CALCRL | “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL2397415 ↗ |